pPB peptide

The pPB peptide is successfully conjugated to pegylated hollow polydopamine nanoparticles, with a molar grafting ratio of 1.50%^[1].
The pPB peptide can be conjugated to form DSPE-PEG-pPB^[2].
Modification with pPB peptide (6 weeks) does not significantly alter the particle size distribution, charge or morphology of SNALPs, and SNALPs modified with 2% pPB remain stable for at least 6 weeks^[2].
The pPB peptide mediates enhanced uptake of SNALPs by hepatic stellate cells (HSCs) through specific binding to the PDGFR-β receptor on HSCs^[2].
Modification with the pPB peptide enhances the gene silencing effects on HSP47 and HMGB1 in hepatic stellate cells (HSCs) by improving the uptake efficiency of SNALP^[2].
The pPB peptide successfully conjugates with DMPE-PEG-Mal to form the DPP construct^[3].
PPB peptide (1 μg/mL; 2 h) mediates PDGFβR-specific, species-nonspecific binding of IFNγ conjugates to mouse NIH3T3 fibroblasts, human LX2 hepatic stellate cells, and primary rat hepatic stellate cells^[4].
The PPB peptide (2 h) significantly reduces TGFβ1-induced collagen expression in mouse NIH3T3 fibroblasts and human LX2 hepatic stellate cells when combined with IFNγ, overcoming the limitation of species-specific IFNγ receptors in human cells^[4].
Conjugation of the PPB peptide with IFNγ mediates the inhibition of PDGF-induced proliferation of mouse NIH3T3 fibroblasts^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.